Traded Aug 4, 2026 · Filed Aug 5, 2026
A board member of Biogen sold $119K of Biogen shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$119,169
Shares × reported transaction price
6 days after results of Jul 29, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $208.45 on Aug 4, 2026, within 4% of its 52-week high, after a 4% rise over the previous 30 trading days
52-week range $127.75 (Aug 7, 2025) to $216.63 (Jun 29, 2026), 91% of the way up, from 251 adjusted closes. 30 trading days earlier: $199.71 on Jun 22, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +2.1% | +1.2% | +0.9% |
| 30 days | +3.0% | -0.3% | +3.4% |
Past results only. Not a forecast.
Compensation award — excluded from discretionary-purchase analysis.
Congress tradeSits on House Ways and Means, Health3 different filers disclosed BIIB within 90 days. Disclosed 14 days after the transaction; reported as an official range, not an exact amount.
A board member of Biogen sold $121K of Biogen shares. Nobody planned it ahead of time.